The Bundibugyo Ebola Outbreak: Why Current Vaccines Fail and the Global Race to Build New Ones

Because of rising case numbers and uncertainty about the true scale of the epidemic, the World Health Organization declared the outbreak a Public Health Emergency of International Concern (PHEIC) in May 2026.

Early official counts reported 246 suspected cases and 80 deaths in the DRC as of mid‑May. Later assessments suggested the number of suspected infections could reach hundreds of cases, though confirmed cases remain lower because laboratory testing is still ongoing.

Why existing Ebola vaccines don’t work for this outbreak

Most people associate “Ebola” with a single virus, but the disease can be caused by several different species of the virus family Orthoebolavirus.

The vaccine currently licensed for Ebola—Ervebo—was designed specifically for Zaire ebolavirus, the strain responsible for the largest and most lethal outbreaks in recent history.

However, the current epidemic is caused by Bundibugyo ebolavirus, a genetically distinct species. Vaccines and antibody treatments built for Zaire ebolavirus have not been proven effective against Bundibugyo virus disease, and there is currently no approved vaccine or targeted treatment for this strain.

This does not mean Ebola vaccines have suddenly stopped working. Instead, the problem is that the available tools were developed for a different species of the virus.

Experimental vaccines being accelerated

With no approved countermeasures, global health organizations are accelerating experimental vaccines designed specifically for the Bundibugyo strain.

Two of the leading candidates include:

1. rVSV‑BDBV vaccine
This candidate uses a recombinant vesicular stomatitis virus (rVSV) platform—similar to the technology behind the licensed Zaire Ebola vaccine—but modified to target the Bundibugyo virus.

2. ChAdOx1 Bundibugyo vaccine
Another candidate uses the ChAdOx1 viral‑vector platform developed at the University of Oxford. Manufacturing support from the Serum Institute of India began under an emergency framework once the outbreak was confirmed.

Early production of doses could potentially occur within two to three months, though further testing—including animal studies—may still be required before deployment.

CEPI and the global response effort

The Coalition for Epidemic Preparedness Innovations (CEPI) has mobilized alongside partners including the World Health Organization, Africa CDC, Gavi, UNICEF, the World Bank, and national health authorities to support vaccine development and outbreak response.

These efforts include:

• accelerating clinical trials and research
• supporting manufacturing of candidate vaccines
• coordinating international funding and preparedness
• assisting affected countries with response logistics and surveillance

Some groundwork for rapid vaccine trials had already been laid during earlier preparedness programs in the region, including collaborations involving CEPI, WHO, and the European Union’s Health Emergency Preparedness and Response Authority (HERA).

The “100 Days Mission” to build vaccines faster

CEPI’s long‑term strategy includes the “100 Days Mission,” an initiative aimed at compressing the timeline from identifying a new pathogen to producing a vaccine candidate within roughly 100 days.

The Bundibugyo outbreak is effectively a real‑world stress test of that idea. Experts warn that producing a fully tested and deployable vaccine within three months remains extremely challenging, especially during an active outbreak in remote areas with limited infrastructure.

Even with accelerated development, issues such as clinical trials, regulatory approval, manufacturing capacity, and cold‑chain distribution can slow deployment.

Why the outbreak is considered urgent

Several factors make the current outbreak particularly concerning:

• No licensed vaccines or treatments exist for the Bundibugyo strain.
• The outbreak has crossed national borders between the DRC and Uganda.
• Case numbers have grown quickly and may still be undercounted due to limited testing and surveillance.

Despite the urgency, global health agencies emphasize that the risk to regions outside the affected area remains low, provided containment measures and surveillance continue to work effectively.

The bigger lesson for pandemic preparedness

The Bundibugyo outbreak illustrates a broader reality of infectious disease control: pathogen families often contain multiple species that require different medical countermeasures.

Even after decades of Ebola research and successful vaccines for some strains, others remain largely unprotected. The current emergency is pushing global health systems to develop faster vaccine pipelines and maintain preparedness between outbreaks.

Whether the new vaccine candidates arrive quickly enough to influence the current epidemic is still uncertain—but the race to build them is already reshaping how the world prepares for future outbreaks.